An official website of the United States government
Identify, characterize, and complete early validation for at least 6 novel therapeutic targets for AD and AD-related dementias (a minimum of 3 targets for pre-symptomatic and early stage disease and a minimum of 3 for advanced disease). These efforts should include therapeutic targets for the neuropsychiatric and behavioral disturbances in AD and ADRDs.
2020 RFA AG 13-013: Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimer's Disease (R01) PAR-18-596: Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01) NOT-AG-18-001 (#9): Neuropsychiatric Symptoms in Alzheimer's Disease (NPS-AD) RFA-MH-19-510: Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01) RFA MH-19-511: Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21) RFA-AG-18-014 Limited Competition: Data Coordinating Center for the Accelerating Medicines Partnership Target Discovery and Preclinical Validation Consortium AMP AD DCC (U24- Clinical Trial Not Allowed) RFA-AG-18-013 Continuation of the AMP AD Target Discovery and Preclinical Validation Consortium (U01 Clinical Trial Optional) 6.C Achieved Identify, characterize, and complete early validation for at least 6 novel therapeutic targets for AD and AD-related dementias… DN 2012 AD Summit: 1A, 1B, 1D, and 5A Blog: Symposium celebrates open science, launches new data platform Blog: Increasing the usability of big data for Alzheimer’s research Blog: Open the portal door to Alzheimer’s Big Data Blog: Open science delivers a wealth of AD/ADRD research data to a portal near you Blog: Seven recent papers amplify advances in Alzheimer’s research Large-scale study of brain proteins uncovers new clues to Alzheimer’s disease Highlight: Study of mouse neurons uncovers novel therapeutic role of removing a genetic variant in the treatment of Alzheimer’s disease Drug Development - Novel Targets AMP AD Target Discovery and Preclinical Validation Project Agora: AMP AD’s Web-based Interactive Platform AMP AD 2.0 Foundational Grants Psych-AD Program Projects funded under PAR-20-157 and PAR-20-159 2014
- Validation based on availability of the following for each novel target: a systems-level understanding of the gene, protein and metabolic networks within which they operate, one or more cell based/animal models that are freely available to the research community, a quantitative assessment of the integrative response to the modulation of the target in one or more model organisms, and identification of pharmacodynamic biomarker(s) for target engagement.
Summary of Key Accomplishments
Through the AMP®AD Target Discovery Program NIA has supported the discovery of over 550 novel candidate targets for AD. More than twenty of these candidate targets have been characterized in cell and animal models. The targets delivered by the AMP AD program along with the supporting data have been made available to researchers in academia and in the biotech/pharmaceutical industry through centralized data infrastructure. Over twelve AMP AD targets are being pursued by industry and in academic labs for new drug discovery efforts targeting multiple aspects of the disease process, such as neuroinflammation, bioenergetic failure and synaptic pathology. The AMP AD data resources have been used by more than 3000 researchers from the US and internationally to advance basic research and therapy development for AD/ADRD.
The key accomplishments summary is current as of March 2022.